The U.S. Food and Drug Administration approved AstraZeneca's durvalumab, known as Imfinzi, in combination with Bacillus Calmette‑Guérin (BCG) on Thursday [1].
This approval provides a new treatment pathway for adult patients with BCG‑naïve, high‑risk non‑muscle‑invasive bladder cancer (NMIBC). By combining immunotherapy with traditional BCG therapy, clinicians may be able to reduce the likelihood of cancer recurrence in a patient population facing high risks of disease progression [2].
The decision follows results from the phase III POTOMAC trial [3]. The study focused on the efficacy of the combination therapy compared to the use of BCG alone. According to trial data, the combination therapy achieved a hazard ratio for disease‑free survival of 0.68 [4].
Statistical analysis of the trial showed a p-value of 0.0154 [4]. These figures indicate that the addition of Imfinzi improved the duration that patients remained free of the disease compared to those receiving only the standard BCG treatment [4].
This represents a key expansion for Imfinzi in the oncology market. While some industry reports noted that earlier attempts to utilize the drug for certain bladder cancer applications were less successful, the specific combination with BCG for high-risk NMIBC proved effective enough to earn the regulatory nod [5].
The FDA approval allows the therapy to be used in the U.S. for patients who have not previously received BCG treatment. This specific patient group, those who are BCG-naïve, now has a validated option to integrate immunotherapy at the start of their treatment regimen [1], [6].
“The FDA approved AstraZeneca's durvalumab, known as Imfinzi, in combination with Bacillus Calmette‑Guérin (BCG).”
The approval of the Imfinzi-BCG combination marks a shift toward using immunotherapy earlier in the treatment cycle for non-muscle-invasive bladder cancer. By targeting BCG-naïve patients, the FDA is expanding the window for intervention, potentially preventing the need for more aggressive surgical options if the disease-free survival rate is maintained across broader clinical use.
